江中药业(600750) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 10.18% to CNY 353,617,590.77 year-to-date[6] - Operating revenue decreased by 1.23% to CNY 1,291,549,708.18 for the first nine months[6] - Total operating revenue for Q3 2018 was CNY 311,621,255.03, a decrease of 10.9% compared to CNY 349,811,074.03 in Q3 2017[35] - Year-to-date revenue reached ¥1,291,549,708.18, slightly decreasing from ¥1,307,645,844.40 year-on-year, a decline of about 1.2%[31] - Total revenue for Q3 2018 was 1,447,812,189.66 CNY, an increase from 1,137,985,594.63 CNY in the same period last year, representing a growth of approximately 27.3%[40] - Net profit for Q3 2018 reached CNY 125,289,147.95, an increase of 13.9% from CNY 110,486,325.48 in Q3 2017[33] - Total profit for Q3 2018 was CNY 141,818,684.91, an increase of 8.5% from CNY 130,861,871.31 in Q3 2017[33] - The total comprehensive income for Q3 2018 was CNY 125,289,147.95, compared to CNY 110,599,375.48 in Q3 2017, indicating an increase of 13.3%[34] Assets and Liabilities - Total assets increased by 5.96% to CNY 3,564,461,883.75 compared to the end of the previous year[6] - Total assets increased to ¥3,566,812,651.65 from ¥3,349,899,707.06, representing a growth of approximately 6.5%[28] - Total liabilities decreased to ¥331,445,951.40 from ¥304,650,717.18, a reduction of about 8.1%[29] - Total equity rose to ¥3,235,366,700.25 from ¥3,045,248,989.88, indicating an increase of approximately 6.2%[29] - The company’s total current assets at the end of the period were 2.13 billion RMB, up from 1.97 billion RMB at the beginning of the year[23] Cash Flow - Cash flow from operating activities increased significantly by 155.91% to CNY 375,362,444.88 year-to-date[6] - Cash and cash equivalents increased to ¥734,397,143.38 from ¥591,944,717.32, a growth of approximately 24.0%[27] - Cash flow from operating activities for the first nine months of 2018 was 375,362,444.88 CNY, significantly higher than 146,676,888.64 CNY in the same period last year[41] - Net cash flow from operating activities was ¥329,566,866.52, up from ¥180,437,722.07 year-over-year[44] - Cash inflow from operating activities primarily derived from sales of goods and services, totaling ¥1,148,763,766.70, compared to ¥873,616,929.47 last year[43] Shareholder Information - The total number of shareholders at the end of the reporting period was 32,136[13] - The largest shareholder, Jiangxi Jiangzhong Pharmaceutical Group, holds 43.03% of the shares, with 22,414,000 shares pledged[13] Expenses and Costs - The gross margin for the pharmaceutical segment was 67.87%, a decrease of 1.52 percentage points year-on-year[9] - Operating costs for Q3 2018 were CNY 123,369,787.25, down from CNY 132,259,936.10 in the same period last year, representing a decrease of 6.7%[35] - The company reported a significant decrease in non-operating expenses by 83.56% to 1.96 million RMB, due to reduced charitable donations[17] - Research and development expenses for Q3 2018 were CNY 6,266,437.49, up 107.5% from CNY 3,017,935.36 in Q3 2017[35] Other Financial Metrics - Basic and diluted earnings per share for Q3 2018 were both CNY 0.30, compared to CNY 0.26 in Q3 2017, reflecting a growth of 15.4%[34] - The income tax expense for Q3 2018 was CNY 16,529,536.96, down from CNY 20,375,545.83 in Q3 2017, representing a decrease of 18.1%[33] - The company reported a total of 381,186,636.50 CNY in cash paid for goods and services in Q3 2018, compared to 341,117,560.14 CNY in Q3 2017, reflecting an increase of approximately 11.0%[40] Strategic Developments - The company has not disclosed any new product developments or market expansion strategies in this report[5] - The company plans to change its actual controller to China Resources Holdings, pending regulatory approval[18]